Search Results

September 30, 2019

U.S. FDA Approves INVOKANA® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD

Learn about the FDA approval of Invokana, a breakthrough in treating diabetic kidney disease and reducing heart failure risk in patients with type 2 diabetes.

Medical technologies

September 27, 2019

Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (apalutamide)

Stay informed with the latest results from the SPARTAN study, showcasing a significant 25% reduction in the risk of death for prostate cancer patients.

Innovative Medicine

September 26, 2019

Janssen Announces U.S. FDA Approval of DARZALEX® (daratumumab) Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma

Approval represents first and only FDA-approved biologic indicated for newly diagnosed patients who are eligible for a stem cell transplant Marks the seventh approved indication for DARZALEX®

4 secrets for fostering an innovative workplace

Johnson & Johnson’s Chief Human Resources Officer reveals how the organization stays forward-thinking after 133 years in business, garnering it a spot on Fast Company‘s inaugural Best Workplaces for Innovators list.

Our Company

September 25, 2019

The face of HIV in the U.S.

Hear from those living with HIV. Learn how Johnson & Johnson is working to #makeHIVhistory.

Innovative Medicine

September 20, 2019

XARELTO® (rivaroxaban) Reduces Recurrent Blood Clots and Total Medical Costs in Morbidly Obese Patients

New real-world study of patients with venous thromboembolism (VTE) and morbid obesity shows safety and effectiveness of XARELTO® were similar to warfarin, with significantly less healthcare resource utilization (HRU) and total medical costs

Innovative Medicine

September 19, 2019

Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019

Second interim analysis from the Phase 3 SPARTAN study reporting updated overall survival results in patients with non-metastatic castration-resistant prostate cancer treated with ERLEADA® (apalutamide) Patient-reported outcomes from the Phase 3 TITAN study evaluating ERLEADA® in patients with metastatic castration-sensitive prostate cancer Interim analysis from the Phase 2 GALAHAD study evaluating niraparib in the treatment of patients with metastatic castration-resistant prostate cancer and biallelic DNA-repair gene defects, featured as late-breaking abstract

Medical technologies

September 19, 2019

U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Phase 3 TITAN is the first registrational study to achieve statistical significance in dual primary endpoints of overall survival and radiographic progression-free survival in patients with mCSPC regardless of extent of disease

Financial

September 18, 2019

Johnson & Johnson to Host Investor Conference Call on Third Quarter Results

Caring & giving

September 13, 2019

The day I met some of Save the Children’s guardian angels: How a program in Bangladesh is helping newborns thrive

Johnson & Johnson’s Chief Human Resources Officer reflects on a life-changing trip he took to Dhaka with the organization—and announces a new $5 million pledge to Save the Children’s Centennial Commitment.

Search Results

No Results

Search Results